Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells

Journal of Thoracic and Cardiovascular Surgery

Volumn 144, Issue 6, 2012, Pages 1479-1485

  Yu, Jessica A ^a   Li, Howard ^a   Meng, Xianzhong ^a   Fullerton, David A ^a   Nemenoff, Raphael A ^a   Mitchell, John D ^a   Weyant, Michael J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; SECRETORY PHOSPHOLIPASE A2;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GROUP II PHOSPHOLIPASES A2; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84869096538     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.08.064     Document Type: Article

References (21)

1. J.L. Marks, S. Broderick, Q. Zhou, D. Chitale, A.R. Li, and M.F. Zakowski Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
2. G.J. Riely, J. Marks, and W. Pao KRAS mutations in non-small cell lung cancer Proc Am Thorac Soc 6 2009 201 205
3. E. Kupert, M. Anderson, Y. Liu, P. Succop, L. Levin, and J. Wang Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer patients with solitary pulmonary nodules BMC Cancer 11 2011 513 523
4. J.A. Yu, MD, D. Mauchley, H. Li, X. Meng, R.A. Nemenoff, D.A. Fullerton, and M.J. Weyant Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo J Thorac Cardiovasc Surg 144 2012 1185 1192
5. 2 inhibition J Thorac Cardiovasc Surg 143 2012 405 411
6. J. Downward Targeting RAS signaling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
7. L.E. Heasley, S. Thaler, M. Nicks, B. Price, K. Skorecki, and R.A. Nemenoff Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer J Biol Chem 279 1997 14501 14504
8. X.Q. Wang, H. Li, V. Van Putten, R.A. Winn, L.E. Heasley, and R.A. Nemenoff Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9 Mol Biol Cell 20 2009 791 800
9. 2 J Thorac Cardiovasc Surg 139 2010 591 599
10. T method Nat Protoc 3 2008 1101 1108
11. J.D. Bradley, A.A. Dmitrienko, A.J. Kivitz, O.S. Gluck, A.L. Weaver, and C. Wisenhutter A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis J Rheumatol 32 2005 417 423
12. D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, and I.F. Dunn Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 114
13. E. Meylan, A.L. Dooley, D.M. Feldser, L. Shen, E. Turk, and C. Ouyang Requirement of NF-κB signalling in a mouse model of lung adenocarcinoma Nature 462 2009 104 107
14. M.R. Sadaria, X. Meng, D.A. Fullerton, T.B. Reece, R.R. Shah, and F.L. Grover Secretory phospholipase A2 inhibition attenuates intercellular adhesion molecule-1 expression in human esophageal adenocarcinoma cells Ann Thorac Surg 91 2011 1539 1545
15. R. Blum, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, and Y. Kloog Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death Cancer Res 65 2005 999 1006
16. P. Van Uden, N.S. Kenneth, and S. Rocha Regulation of hypoxia-inducible factor-1α by NF-κB Biochem J 412 2008 477 484
17. F. Granata, A. Frattini, S. Loffredo, R.I. Staiano, A. Petraroli, and D. Ribatti Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2 J Immunol 184 2010 5232 5241
18. P.S. Hammerman, M.L. Sos, A.H. Ramos, C. Xu, A. Dutt, and W. Zhou Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 1 2011 78 89
19. Z. Dong, Y. Liu, K.F. Scott, L. Levin, K. Gaitonade, and R.B. Bracken Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer Carcinogenesis 31 2010 1948 1955
20. K. Krysan, K.L. Reckamp, H. Dalwadi, S. Sharma, E. Rozengurt, and M. Dohaldwala Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner Cancer Res 65 2005 6275 6281
21. M. Hernández, R. Martín, M.D. García-Cubillas, P. Maeso-Hernández, and M.L. Nieto Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link Neuro Oncol 12 2010 1014 1023